Market research
9U9.F Unity Biotechnology, Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 6.86
- Dividend yield
- 0.0%
- Beta
- 0.74
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 6.86
- Dividend yield
- 0.0%
- Beta
- 0.74
About
About Unity Biotechnology, Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Research context
Unity Biotechnology, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 9U9.F discussion.
5 years, 7 months ago
Unity Biotechnology, Inc is currently in a long term downtrend where the price is trading 21.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Unity Biotechnology, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 8.7% to $-20M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.6% to $-17M since the same quarter in the previous year.
Based on the above factors, Unity Biotechnology, Inc gets an overall score of 1/5.